NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
ZERVIATE (cetirizine) by Ichnos Glenmark Innovation is histamine h1 receptor antagonists [moa]. Approved for allergic rhinitis, chronic urticaria, atopic dermatitis. First approved in 2017.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZERVIATE is a cetirizine hydrochloride ophthalmic solution approved by the FDA on May 30, 2017, for the treatment of itching associated with allergic conjunctivitis caused by hay fever and other upper respiratory allergies. It works as a histamine H1 receptor antagonist, blocking histamine-mediated allergic responses in the eye. This product represents a novel ophthalmic formulation of a well-established systemic antihistamine, offering localized ocular delivery for symptoms including itchy, watery eyes and nasal symptoms.
$0.0BPart D
6.7 years to LOEMechanism of Action
Histamine H1 Receptor Antagonists
Pharmacologic Class:
Histamine-1 Receptor Antagonist
Indications (3)
Worked on ZERVIATE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.